News - Page 2 of 8 - SAB BIO

Big Cypress Acquisition Corp. Announces Confidential Submission of S-4 Registration Statement Related to Proposed Business Combination with SAB Biotherapeutics

SAB Biotherapeutics Doses First Participant in Phase 2a Trial of SAB-176 for the Treatment of Influenza

June 29, 2021

SAB Biotherapeutics to List on Nasdaq through Merger with Big Cypress Acquisition Corp.

June 22, 2021

SAB Biotherapeutics to Participate in Expert Panel at BIO Digital 2021

June 14, 2021

SAB Biotherapeutics Appoints Carlos Carrillo, PhD, as Senior Vice President, Regulatory Affairs

June 10, 2021

SAB Biotherapeutics to Present at RBC Capital Markets 2021 Global Healthcare Conference

SAB Biotherapeutics Doses First Patient with SAB-185 for the Treatment of COVID-19 in NIH’s ACTIV-2 Phase 2/3 Clinical Trial

April 21, 2021

SAB Biotherapeutics Strengthens Senior Management Team with Appointment of Kipp Erickson, PhD as Chief Operating Officer

April 13, 2021

SAB Biotherapeutics to Present at Upcoming March Investor Conferences

March 4, 2021

SAB Biotherapeutics Announces New Appointments to its Board of Directors

December 15, 2020

SAB Biotherapeutics Awarded $57.5M from BARDA and U.S. Department of Defense for Manufacturing of SAB-185 for the Treatment of COVID-19

November 30, 2020

SAB Biotherapeutics Announces First Patient Dosed In Phase 1b Clinical Trial Of SAB-185 For The Treatment Of COVID-19

August 21, 2020